Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted
Source: SeekingAlpha
2025-10-10 17:18:54 ET
Shares of biopharmaceutical concern Monopar Therapeutics Inc. ( MNPR ) have had an absolutely massive surge in the past year after being left for dead with cash of $7.1 million and a market cap under $9 million. Its acquisition of Wilson disease candidate ALXN-1840 and a positive result from its imaging and dosimetry candidate MNPR-101-Zr are responsible for the remarkable turnaround. With an operating runway through YE26, an anticipated NDA filing for ALXN-1840 in early 2026, along with new and positive Street sponsorship, the surge in Monopar merited a deeper dive. An analysis follows below....
Read the full article on Seeking Alpha
For further details see:
Monopar Therapeutics: A Healthy Dose Of Skepticism Warranted
Monopar Therapeutics Inc.
NASDAQ: MNPR
MNPR Trading
3.73% G/L:
$58.625 Last:
74,240 Volume:
$57.82 Open:
MNPR Latest News
March 02, 2026 08:00:00 am
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
November 13, 2025 08:00:00 am
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
MNPR Stock Data
$384,114,928
4,169,932
0.03%
12
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmette
